Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Pulmonology Reports
Erschienen in: Current Pulmonology Reports 4/2014

01.12.2014 | Respiratory Infections (C Daley, Section Editor)

Diagnosis and management of nontuberculous mycobacterial lung infections

verfasst von: Teng Moua, Timothy R. Aksamit

Erschienen in: Current Pulmonology Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The diagnosis and management of nontuberculous mycobacterial (NTM) lung infection remains difficult even among experienced clinicians. Both the incidence and prevalence are likely expected to rise with an aging population. Careful assessment of clinical, radiologic, and microbiologic studies is warranted before initiating therapy, which is often complicated by significant drug side effects and limited sputum conversion rates. Indications to treat are best based on a number of factors, including specific NTM species, NTM lung-infection–associated symptoms, advanced bronchiectatic or cavitary disease, expected tolerance of therapy, and related comorbidities. Surgical resection of localized disease or refractory infection may warrant consideration, but should be done by an experienced surgeon and mycobacterial program. Increased awareness and treatment of NTM lung infection in recent years is likely due to earlier recognition and improved treatment strategies, though the approach to the NTM lung infection patient most often involves chronic lung disease management. NTM lung infection is perhaps is best characterized as a treatable lung infection, even without universally curable outcomes.
Literatur
1.
Griffith DE et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.PubMedCrossRef
2.•
Hoefsloot W et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13. This study provides global epidemiologic data highlighting differences that have been observed for many years. It also provides a model and template for epidemiologists and clinicans to be mindful of the distribution of NTM specific species and solidify a microbiologic diagnosis prior to treatment when indicated.
3.
4.
Thomson R et al. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol. 2013;51(9):3006–11.PubMedCentralPubMedCrossRef
5.
Marras TK et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest. 2005;127(2):664–71.PubMedCrossRef
6.
Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect. 2003;18(1):33–9.PubMedCrossRef
7.
Hanak V et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir Med. 2006;100(4):610–5.PubMedCrossRef
8.
Maekawa K et al. Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease. Chest. 2011;140(3):723–9.PubMedCrossRef
9.
Kim RD et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066–74.PubMedCentralPubMedCrossRef
10.
Dirac MA et al. Environment or host?: A case–control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186(7):684–91.PubMedCrossRef
11.
Falkinham 3rd JO. Reducing human exposure to Mycobacterium avium. Ann Am Thoracic Soc. 2013;10(4):378–82.CrossRef
12.
Prevots DR et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–6.PubMedCentralPubMedCrossRef
13.
Winthrop KL et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977–82.PubMedCrossRef
14.•
\Adjemian J et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881–6. Investigators very nicely capture an overview of United States NTM distribution using a Medicare data base, in patients aged 65 years and older, derived from billing diagnoses. Although there are inherent biases and limitations using this type of data base, the analysis provides a more comprehensive look at the distribution of NTM disease across the US than has previously been available. It provides a basis for asking additional probing research questions into the distribution of NTM lung infection and potential links to environmental exposures.
15.
16.
Kim JK, Rheem I. Identification and distribution of nontuberculous mycobacteria from 2005 to 2011 in cheonan. Korea Tubercul Respir Dis. 2013;74(5):215–21.CrossRef
17.
Morimoto K et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thoracic Soc. 2014;11(1):1–8.CrossRef
18.
Hoefsloot W et al. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J Infect. 2013;66(6):542–5.PubMedCrossRef
19.
Ko FW et al. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest. 2007;131(1):44–52.PubMedCrossRef
20.
Griffith DE, Aksamit TR. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med. 2012;33(2):283–95.PubMedCrossRef
21.
Martiniano SL et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thoracic Soc. 2014;11(1):36–44.CrossRef
22.
Roux AL et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol. 2009;47(12):4124–8.PubMedCentralPubMedCrossRef
23.
Binder AM et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med. 2013;188(7):807–12.PubMedCentralPubMedCrossRef
24.
Olivier KN. The natural history of nontuberculous mycobacteria in patients with cystic fibrosis. Paediatr Respir Rev. 2004;5(Suppl A):S213–6.PubMedCrossRef
25.
Olivier KN et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):828–34.PubMedCrossRef
26.
Fowler SJ et al. Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics. Eur Respir J. 2006;28(6):1204–10.PubMedCrossRef
27.
Koh WJ et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest. 2007;131(6):1825–30.PubMedCrossRef
28.
Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med. 2002;23(3):643–53.PubMedCrossRef
29.•
Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Med. 2014;108(3):417–25. This summary article further highlights many of the controversies that NTM lung infection patients and clinicians caring for them frequently encounter. Although answers to the controversies are not yet available, this reference highlights the context from which additional research questions are to be posed. PubMedCrossRef
30.
Mayskaya MU et al. Morphological manifestations of the atypical mycobacteriosis caused by nontuberculous mycobacteria in the HIV infected patients. Ann Clin Lab Sci. 2014;44(2):131–3.PubMed
31.
Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis. 2012;31(4):397–403.PubMedCrossRef
32.
33.
Ballarino GJ et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009;103(10):1448–55.PubMedCentralPubMedCrossRef
34.
Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis. 1991;143(6):1381–5.PubMedCrossRef
35.
Billinger ME et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998–2005. Emerg Infect Dis. 2009;15(10):1562–9.PubMedCentralPubMedCrossRef
36.
Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013;34(1):110–23.PubMedCrossRef
37.••
Kartalija M et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013;187(2):197–205. This is a very important reference along with its predecessor from the NIH (ref 9 above Kim et al.) that captures the distinctive phenotype of the most common presentation and features of NTM lung infection in the United States. Moreover, these two papers highlight the subtle differences in measurement of immunotypes that may impact the link between ubiquitous exposure to NTM in the environment and development of lung infection. In a similar fashion, subtle differences in methodology of measurement of immune responses may heavily influence whether abnormal responses can be differentiated from normal responses.PubMedCrossRef
38.
Paulson ML, Olivier KN, Holland SM. Pulmonary non-tuberculous mycobacterial infection in congenital contractural arachnodactyly. Int J Tubercul Lung Dis. 2012;16(4):561–3.CrossRef
39.
Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. Lady Windermere Syndr Chest. 1992;101(6):1605–9.
40.
Iseman MD et al. Disease due to Mycobacterium avium-intracellulare. Chest. 1985;87(2 Suppl):139S–49.PubMedCrossRef
41.
Prince DS et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989;321(13):863–8.PubMedCrossRef
42.
Kuroishi S et al. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J. 2008;32(1):147–52.PubMedCrossRef
43.
Maekawa K et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tubercul Lung Dis. 2013;17(6):829–35.CrossRef
44.
Kitada S et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J. 2013;42(2):454–60.PubMedCrossRef
45.
van Ingen J et al. Chapter 3. Pulmonary diseases caused by non-tuberculous mycobacteria. Eur Respir Monogr. 2012;58:25–37.
46.
Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc. 1999;74(1):45–51.PubMedCrossRef
47.
Ito Y et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tubercul Lung Dis. 2012;16(3):408–14.CrossRef
48.
Marras TK et al. Opinions differ by expertise in Mycobacterium avium complex disease. Ann Am Thoracic Soc. 2014;11(1):17–22.CrossRef
49.
Koh WJ et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest. 2012;142(6):1482–8.PubMedCrossRef
50.
Kobashi Y et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother. 2006;12(4):195–202.PubMedCrossRef
51.
van Ingen J et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updates. 2012;15(3):149–61.CrossRef
52.
Davis KK et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulmonary Med. 2007;7:2.CrossRef
53.
Colin AA, Ali-Dinar T. Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. Pediatr Pulmonol. 2010;45(6):626–7.PubMed
54.•
Wallace, R.J., Jr., et al., Macrolide/Azalide Therapy for Nodular/Bronchiectatic: Mycobacterium avium Complex Lung Disease. Chest, 2014. This is an important recent large series of 180 patients with MAC nodular/bronchiectatic MAC lung infection. It highlights the efficacy of the ATS recommended thrice weekly mycobactial regimen with favorable sputum conversion rates yet with substantially less side effects and intolerance compared to a daily mycobacterial regimen.
55.
Koh WJ et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57(5):2281–5.PubMedCentralPubMedCrossRef
56.
Griffith DE et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928–34.PubMedCrossRef
57.
Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003;124(4):1482–6.PubMedCrossRef
58.
Kemper CA et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis. 1994;170(1):157–64.PubMedCrossRef
59.
Wallace Jr RJ et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171(3):747–50.PubMedCrossRef
60.
Koh WJ et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;186(8):797–802.PubMedCrossRef
61.
van Ingen J et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559–65.PubMedCrossRef
62.
van Ingen J et al. Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tubercul Lung Dis. 2010;14(1):99–105.
63.
Mitchell JD et al. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85(6):1887–92. discussion 1892–3.PubMedCrossRef
64.
Griffith DE, Girard WM, Wallace Jr RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993;147(5):1271–8.PubMedCrossRef
65.•
Jarand J et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52(5):565–71. This study offers clinicians some encouragement, along with studies of Jeon et al. ref 66 and Lyu et ref 69, that modest sputum culture rates may be possible in select M. abscessus lung infection patients. Differentiation of M. abscessus ssp. abscessus from ssp. massiliense is not included. These studies offer a look into the complexity of the variety of multidrug regimens often used. Side effects and drug intolerance remain substantial and further highlight the need for the development of more effective, easier, and better tolerated treatment regimens.
66.
Jeon K et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009;180(9):896–902.PubMedCrossRef
67.
Nash KA, Brown-Elliott BA, Wallace Jr RJ. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53(4):1367–76.PubMedCentralPubMedCrossRef
68.
Choi GE et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917–25.PubMedCrossRef
69.
Lyu J et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med. 2011;105(5):781–7.PubMedCrossRef
70.
Shitrit D et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999–2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129(3):771–6.PubMedCrossRef
71.
Takahashi M et al. Mycobacterium kansasii pulmonary infection: CT findings in 29 cases. Jpn J Radiol. 2012;30(5):398–406.PubMedCrossRef
72.
Bittner MJ et al. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis. 1996;22(6):1109–10.PubMedCrossRef
73.
Wallace Jr RJ et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18(5):736–43.PubMedCrossRef
74.
Maliwan N, Zvetina JR. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad Med J. 2005;81(958):530–3.PubMedCentralPubMedCrossRef
75.
Krisher KK, Kallay MC, Nolte FS. Primary pulmonary infection caused by Mycobacterium terrae complex. Diagn Microbiol Infect Dis. 1988;11(3):171–5.PubMedCrossRef
76.
Mazumder SA, Hicks A, Norwood J. Mycobacterium gordonae pulmonary infection in an immunocompetent adult. N Am J Med Sci. 2010;2(4):205–7.PubMedCentralPubMed
77.
Wong C et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–7.PubMedCrossRef
78.
Altenburg J et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9.PubMedCrossRef
79.
Serisier DJ et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–7.PubMedCrossRef
80.
Mirsaeidi M et al. Nontuberculous mycobacterial disease mortality in the United States, 1999–2010: a population-based comparative study. PLoS ONE. 2014;9(3):e91879.PubMedCentralPubMedCrossRef
Metadaten
Titel
Diagnosis and management of nontuberculous mycobacterial lung infections
verfasst von
Teng Moua
Timothy R. Aksamit
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Pulmonology Reports / Ausgabe 4/2014
Elektronische ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-014-0090-4

Weitere Artikel der Ausgabe 4/2014

Current Pulmonology Reports 4/2014 Zur Ausgabe

Smoking Cessation (S Veeraraghavan, Section Editor)

Legalizing Cannabis: A physician’s primer on the pulmonary effects of marijuana

Respiratory Infections (C Daley, Section Editor)

Management of chronic rhinosinusitis

Mediastinal Diseases (D. Hsia, Section Editor)

Primary mediastinal B-cell lymphoma

Interstitial Lung Disease (G. Tino, Section Editor)

Fibrotic hypersensitivity pneumonitis

Smoking Cessation (S Veeraraghavan, Section Editor)

Electronic nicotine delivery systems for smoking cessation: where are we?

Lung Transplate (M Zamora, Section Editor)

Gastroesophageal reflux disease and the lung transplant recipient

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | DGIM 2024 | Nachrichten

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise